医药ASCO2016赫赛汀生物仿制

Chaprbrastcancrdrugdoswllinclinicaltrial

(HalthDay)—ForwomnwithadvancdHER2-positivbrastcancr,asimilarbutlssxpnsivxprimntaldrugworksjustaswllasthstandarddrugHrcptin(trastuzumab),anwstudyfinds.

HER2-positivtumorscontaincrtaingnsthatarassociatdwithmorrapidtumorgrowthandaworsprognosis,accordingtothAmricanCancrSocity.

Thnwdrugtargtingthstumorsiswhatsknownasabiosimilardrug—inthiscas,adrugsimilartoHrcptin.Biosimilarsardsigndtomimicthbrand-nammdicin,andarxpctdtoproducroughlythsamrsultsinpatints,thU.S.FoodandDrugAdministrationxplaind.

RsarchrsconductdarandomizdphasIIIclinicaltrialofthbiosimilartrastuzumabantibodydrugMYL-O.Thirtrialincluddpatints.Thtrialwasconductdat95sitsinAfrica,Asia,EuropandLatinAmrica.

ThwomnrcivdchmothrapyandithrHrcptinorMYL-Oforatlastightcycls,followdbyHrcptinalonuntilthirdisasprogrssd.

Sixmonthslatr,rsponsratswrsimilarinbothgroups,70prcntwithMYL-Oand64prcntwithHrcptin,thstudyfound.

Ratsofsrioussidffctswralsosimilar—36prcntinthHrcptingroupand38prcntinthMYL-Ogroup.Thmost







































皮肤白癜风的治疗方法
白癜风怎样能治好

转载请注明：http://www.taolele168.com/jbtx/6210.html